Navigation Links
TPI Attends 23rd ROTH Annual OC Growth Stock Conference from March 13-16, 2011
Date:3/11/2011

CHENGDU, China, March 11, 2011 /PRNewswire-Asia-FirstCall/ --Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals is invited to present at the 23rd ROTH Annual OC Growth Stock Conference from March 13 - 16, 2011 at the Ritz Carlton in Dana Point, California.

Dr. James Jiayuan Tong, Chief Financial Officer, Chief Business & Development Officer and Board Director of the Company will present at 8:30 am, March 16, at track 2 of the Conference.

An updated Company's presentation can be found on the Investors Relations of www.tianyinpharma.com

About TPITPI, headquartered at Chengdu, China, is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical medicine, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. TPI currently manufactures a comprehensive portfolio of 56 products, 23 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI currently has a pipeline of 10 late stage products pending the SFDA approval that target various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

More information regarding the Company can be found at: http://www.tianyinpharma.com.

Safe Harbor StatementThe Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.For more information, please contact:James Jiayuan Tong M.D. Ph.D.Chief Financial Officer, Chief Business & Development OfficerDirectorTianyin Pharmaceutical Co., Inc.Web:
http://www.tianyinpharma.comEmail:   Dr.Tong@tianyinpharma.comTel:
+86-28-8551-6696 (Chengdu, China)+86-134-3655-0011 (China)+1-949-350-6999 (U.S.)Address: 23rd Floor Unionsun Yangkuo PlazaNo 2 Block 3 South Renmin RoadChengdu, 610041China
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Curemark Attends North American Bio Forum at Canadian Government Invitation
2. US Oncology Clinical Development Attends Partnerships With CROs
3. Palatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference
4. UBM Announces Content for 10th Annual Japanese Pharma & Bio Events
5. 6th Annual Szent-Gyorgyi Prize for Progress in Cancer Research Awarded to Beatrice Mintz, Ph.D.
6. Talecris Biotherapeutics Announces Record Date for 2011 Annual Meeting of Shareholders
7. NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8
8. BioSpecifics Technologies Corp. to Present at Cowen and Company 31st Annual Health Care Conference
9. Amgen to Present at the Cowen and Company 31st Annual Healthcare Conference
10. Huifeng Bio-Pharmaceutical Technology, Inc. to Present at the 2011 Rodman & Renshaw Annual China Investment Conference in Shanghai
11. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Jolla, CA (PRWEB) , ... December 08, 2016 , ... ... 2016 was a banner year for team building events, new program offerings and company ... which it expanded earlier this year to include groups of over 30 people. Ever ...
(Date:12/8/2016)... DIEGO , Dec. 8, 2016  Renova™ ... for congestive heart failure and type 2 diabetes, ... for a novel adeno-associated virus (AAV) vector developed ... , M.D., Ph.D., at Stanford University. The company ... its paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... -- Oxford Gene Technology (OGT), The ... range with the launch of the SureSeq myPanel™ NGS Custom ... in familial hypercholesterolemia (FH). The panel delivers single nucleotide variation ... small panel and allows customisation by ,mix and match, of ... LDLR , P C SK9 , ...
(Date:12/8/2016)... ... 08, 2016 , ... This CAST literature review and report looks at problems ... on the economic effects in countries that are major global commodity exporters and importers, ... resultant risk of low level presence (LLP) puts large volumes of trade worth billions ...
Breaking Biology Technology:
(Date:11/14/2016)... Fla., Nov. 14, 2016  xG Technology, Inc. ("xG" ... providing critical wireless communications for use in challenging operating ... September 30, 2016. Management will hold a conference call ... 5:00 p.m. Eastern Time (details below). Key ... a $16 million binding agreement to acquire Vislink Communication ...
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
(Date:6/16/2016)... The global Biometric ... USD 1.83 billion by 2024, according to a ... proliferation and increasing demand in commercial buildings, consumer ... the market growth.      (Logo: ... of advanced multimodal techniques for biometric authentication and ...
Breaking Biology News(10 mins):